DexCom(US:DXCM) Globenewswire·2025-11-10 20:32Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging misleading statements and undisclosed risks related to the company's glucose monitoring products [1][3]. Summary by Sections Allegations - The complaint claims that during the class period from July 26, 2024, to September 17, 2025, DexCom made unauthorized design changes to its G6 and G7 glucose monitoring devices, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes allegedly made the G6 and G7 devices less reliable, posing a material health risk to users who depend on them for accurate glucose readings [3]. - The enhancements claimed for the G7 device, including its reliability and accuracy, were reportedly overstated by the defendants [3]. - The true scope and severity of the issues with the G7 devices were downplayed, increasing the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [3]. - As a result, the public statements made by the defendants were considered materially false and misleading throughout the relevant period [3]. Next Steps for Shareholders - Shareholders who purchased shares of DXCM during the specified class period are encouraged to register for the class action by December 26, 2025, to potentially be appointed as lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who have suffered losses due to misleading statements or omissions [5].